SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute ("TTAM"), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former C ...

Core Viewpoint - 23andMe has entered into a definitive agreement to sell substantially all of its assets to TTAM Research Institute for $305 million, following a competitive bidding process that included Regeneron Pharmaceuticals as a backup bidder [2][3]. Group 1: Transaction Details - The sale includes the Personal Genome Service (PGS), Research Services business lines, and Lemonaid Health business [2]. - The transaction is subject to approval by the U.S. Bankruptcy Court, with a hearing scheduled for June 17, 2025 [7]. - The agreement with TTAM will replace a previously announced acquisition agreement with Regeneron for $256 million [5]. Group 2: Privacy and Consumer Protections - TTAM has committed to comply with 23andMe's privacy policies and applicable laws, ensuring customer data is processed according to existing consents and privacy statements [4]. - Additional consumer protections include honoring customer rights to delete accounts and genetic data, notifying customers before closing, and establishing a Consumer Privacy Advisory Board within 90 days [6]. - TTAM will offer two years of free identity theft monitoring to customers and will continue to allow de-identified data to be used for research [6].